IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares Bought by B.O.S.S. Retirement Advisors LLC

B.O.S.S. Retirement Advisors LLC raised its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 3.6% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 4,771 shares of the company’s stock after acquiring an additional 168 shares during the period. B.O.S.S. Retirement Advisors LLC’s holdings in IDEXX Laboratories were worth $2,396,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently bought and sold shares of IDXX. Moneta Group Investment Advisors LLC boosted its stake in IDEXX Laboratories by 121,647.2% in the fourth quarter. Moneta Group Investment Advisors LLC now owns 7,447,279 shares of the company’s stock valued at $3,038,192,000 after acquiring an additional 7,441,162 shares during the period. Norges Bank acquired a new position in shares of IDEXX Laboratories during the fourth quarter worth approximately $336,416,000. Alliancebernstein L.P. boosted its position in shares of IDEXX Laboratories by 11.5% during the fourth quarter. Alliancebernstein L.P. now owns 3,240,710 shares of the company’s stock worth $1,322,080,000 after buying an additional 334,020 shares during the period. Morgan Stanley boosted its position in shares of IDEXX Laboratories by 36.0% during the fourth quarter. Morgan Stanley now owns 986,232 shares of the company’s stock worth $402,344,000 after buying an additional 260,926 shares during the period. Finally, Winslow Capital Management LLC boosted its position in shares of IDEXX Laboratories by 31.4% during the fourth quarter. Winslow Capital Management LLC now owns 873,084 shares of the company’s stock worth $356,183,000 after buying an additional 208,387 shares during the period. 86.85% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities analysts have recently issued reports on IDXX shares. JPMorgan Chase & Co. boosted their price objective on IDEXX Laboratories from $550.00 to $600.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 2nd. Morgan Stanley boosted their target price on IDEXX Laboratories from $590.00 to $600.00 and gave the stock an “overweight” rating in a report on Thursday, August 3rd. Atlantic Securities cut IDEXX Laboratories from an “overweight” rating to a “neutral” rating and set a $610.00 target price on the stock. in a report on Wednesday, August 2nd. Stifel Nicolaus dropped their target price on IDEXX Laboratories from $525.00 to $500.00 and set a “hold” rating on the stock in a report on Friday. Finally, StockNews.com assumed coverage on IDEXX Laboratories in a report on Thursday, August 17th. They set a “buy” rating on the stock. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat.com, IDEXX Laboratories has an average rating of “Moderate Buy” and a consensus target price of $571.67.

IDEXX Laboratories Trading Down 2.5 %

NASDAQ IDXX traded down $11.39 on Friday, hitting $450.69. 770,079 shares of the stock were exchanged, compared to its average volume of 452,822. IDEXX Laboratories, Inc. has a 52-week low of $317.06 and a 52-week high of $564.73. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.33 and a quick ratio of 0.89. The company has a market capitalization of $37.41 billion, a price-to-earnings ratio of 47.84, a P/E/G ratio of 2.66 and a beta of 1.20. The company’s 50-day moving average price is $511.69 and its two-hundred day moving average price is $490.61.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings data on Tuesday, August 1st. The company reported $2.67 earnings per share for the quarter, topping the consensus estimate of $2.43 by $0.24. IDEXX Laboratories had a net margin of 22.52% and a return on equity of 104.84%. The firm had revenue of $943.63 million for the quarter, compared to analysts’ expectations of $927.84 million. Research analysts predict that IDEXX Laboratories, Inc. will post 9.82 EPS for the current year.

Insider Activity

In other news, CEO Jonathan Jay Mazelsky sold 13,424 shares of the business’s stock in a transaction on Thursday, August 31st. The shares were sold at an average price of $512.01, for a total transaction of $6,873,222.24. Following the transaction, the chief executive officer now directly owns 72,925 shares in the company, valued at approximately $37,338,329.25. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. In other IDEXX Laboratories news, EVP Michael Lane sold 16,027 shares of the business’s stock in a transaction on Thursday, August 3rd. The shares were sold at an average price of $510.00, for a total transaction of $8,173,770.00. Following the completion of the transaction, the executive vice president now owns 4,034 shares of the company’s stock, valued at approximately $2,057,340. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Jonathan Jay Mazelsky sold 13,424 shares of the company’s stock in a transaction dated Thursday, August 31st. The shares were sold at an average price of $512.01, for a total transaction of $6,873,222.24. Following the transaction, the chief executive officer now directly owns 72,925 shares of the company’s stock, valued at approximately $37,338,329.25. The disclosure for this sale can be found here. Insiders have sold a total of 52,360 shares of company stock worth $26,743,411 in the last ninety days. Corporate insiders own 2.11% of the company’s stock.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.